Frontlight ResearchEarly access
CompletedPhase 1/2
First test of RJVA-001, given into the pancreas, in adults with type 2 diabetes
Tests the safety of RJVA-001 in adults whose type 2 diabetes is poorly controlled.
Key facts
- Who runs it
- Fractyl Health Inc.
- Where
- Amsterdam, NetherlandsSee the site
- Trial code
- EU 2025-524438-24-00
- U1111-1331-8762
- Registry title
- The RJVA-001 First in Human Trial in Adults with Inadequately Controlled Type 2 Diabetes.
- Status
- Completed
- Phase
- Phase 1/2
- People taking part
- 15 people enrolled
- Started
- 8 Sept 2026
- Ended
- 22 Oct 2026
- Type of study
- Interventional
- Record updated
- 19 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 35 to 70 with type 2 diabetes that is not well controlled on several glucose-lowering medicines, including a GLP-1RA. It tests the safety of RJVA-001 given by endoscopic ultrasound into the pancreas.
- Age
- 35 to 70 years (inclusive)
- Sex
- All sexes can join.
- Disease stage
- Type 2 diabetes, not well controlled on several glucose-lowering medicines. Adding or changing treatment is judged unacceptable by the investigator. Insulin therapy has been deferred.
- Earlier treatment
- Must already take a GLP-1RA at the maximum tolerated maintenance dose, with ongoing benefit, plus permitted non-insulin glucose-lowering medicines. No new weight loss medicines during the study.
- Biomarker or test result
- Normal calcitonin level and normal thyroid function. Fasting plasma glucose, hemoglobin A1c, body mass index and random C-peptide levels must be as stated in the study protocol.
Main reasons for not taking part
- Type 1 diabetes, a history of ketoacidosis, monogenic diabetes, latent autoimmune diabetes of adults, or islet cell autoantibodies
- History of chronic or acute pancreatitis
- History of dose-limiting side effects from GLP-1RA medicines
- History of active malignancy, or medullary thyroid carcinoma in the person or family
- Contraindication to upper gastrointestinal endoscopy, to sedation or anesthesia, or to steroids or sirolimus
The registry criteria, word for word
Show all 47 criteriaShow less
Who can take part
- Signed and dated written informed consent in accordance with Good Clinical Practice and local legislation
- Normal calcitonin level as stated in the study protocol
- Based on Investigator’s judgement, continuous dose escalation or modification of participant’s current treatment regimen is deemed unacceptable
- Participant has deferred insulin therapy
- Able to tolerate a once-weekly injectable, once-daily injectable or oral GLP-1RA treatment as evidenced by ongoing treatment and benefit from GLP-1RAs at an efficacious dose
- Participants must be willing to abstain from semen/blood donation through 1 year after RJVA-001 injection
- Participants must be willing to abstain from alcohol use until completion of the sirolimus taper
- Participants must agree not to initiate any new or intensive diet or exercise regimens and/or any new weight loss medications during study participation
- Age 35 to 70 years (inclusive)
- Agree to use appropriate form of contaception for the study duration and for at least 1 year after RJVA-001 infusion
- Diagnosis of Type 2 Diabetes
- Body mass index as indicated in the study protocol
- Fasting plasma glucose and hemoglobin A1c levels as stated in the study protocol
- Participants are taking glucagon-like peptide-1 receptor agonists (GLP-1RA) at the maximum tolerated maintenance dose and taking permitted non-insulin glucose lowering agents other than GLP-1RA
- Random C-peptide level as stated in the study protocol
- Normal thyroid function as defined in the study protocol
Who cannot take part
- Intake of an investigational drug within 5 half-lives prior to visit 1 or active participation in another clinical trial of an investigational drug or device
- Contraindication to systemic steroids or sirolimus
- Participant is on a weight loss program and is not in the weight maintenance phase, or is on a GLP-1 weight loss medication
- History of non-adherence to diabetes treatment in the previous 6 months, as determined by the Investigator
- Concomitant Medication Exclusions as stated in the study protocol
- Immunization with live vaccines within 30 days prior to screening, Visit 1
- Diagnosis of Type 1 diabetes or history of ketoacidosis, monogenic diabetes or latent autoimmune diabetes of adults or presence of 1 or more islet cell autoantibodies
- History of clinically significant valvular heart disease or severe aortic stenosis
- Acute coronary syndrome, stroke or transient ischemic attack as stated in the study protocol
- History of dose-limiting persistent adverse side effects from GLP-1RA use
- History of severe peripheral vascular disease
- History of active malignancy or partial remission from clinically significant malignancy, personal or familial history of medullary thyroid carcinoma as stated in the study protocol
- Suspected GI malignancy
- History of blood dyscrasias or any disorders causing hemolysis or unstable erythrocytes
- History of alcohol or illicit substance abuse as stated in the study protocol
- Participant has poorly controlled hypertension as defined in the study protocol
- Any other clinical or mental condition which, in the opinion of the Investigator, would jeopardize participant’s safety or makes participant a poor candidate for clinical trial participation
- Known history of diabetic retinopathy
- Active systemic infection or undergoing treatment for recent infection. Does not apply to completely treated infection
- Condition(s) requiring systemic immunomodulation or whose immune status makes the participant a poor candidate for clinical trial participation
- History of chronic or acute pancreatitis, or elevated fasting triglycerides as stated in the study protocol
- Family history of hemochromatosis or cystic fibrosis, as self-reported by the participants will be documented
- History of tuberculosis
- Known hypersensitivity or allergy to eggs, milk, wheat, or [13C]-labeled Spirulina substrates
- History of hepatic decompensation/acute liver disease, acute or chronic active hepatitis B or C, alcoholic or autoimmune chronic hepatitis as stated in the study protocol. Known portal hypertension
- Laboratory and Radiographic Exclusions as stated in the study protocol
- History of symptomatic heart failure with reduced or preserved ejection fraction
- General contraindications to deep or conscious sedation or general anesthesia or high risk as determined by anesthesiologist
- Contraindications to upper gastrointestinal (GI) endoscopy
- Symptomatic cholelithiasis or cholecystitis unless treated by cholecystectomy
- Any contraindications to the infusate to be delivered
Where in Netherlands
- Amsterdam UMC StichtingAmsterdam, NetherlandsNo longer taking part
About the trial
What the trial wants to find out
To evaluate the safety and tolerability of RJVA-001.
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- A Phase 1/2 Open-Label, Single Ascending Dose, First-In-Human Study to Assess Safety and Tolerability of Endoscopic Ultrasound-Guided Pancreatic Infusion of RJVA-001 in Adults With Inadequately Controlled Type 2 Diabetes on Multiple Glucose-Lowering Agents.
- Plain-language title
- First test of RJVA-001, given into the pancreas, in adults with type 2 diabetesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 19 October 2026